Researchers at the University of Sydney developed a nasal spray using mRNA technology to prevent cognitive decline associated with Alzheimer’s disease in animal models.
The treatment delivers messenger RNA straight to the brain via the nasal mucosa, bypassing the blood-brain barrier.
Greg Neely and his team built a liquid formulation that uses lipid nanoparticles to encapsulate mRNA designed to manufacture brain-derived neurotrophic factor, or BDNF. BDNF levels drop significantly in the hippocampus and entorhinal cortex of patients with Alzheimer’s disease.
Administering the treatment to aging mice improved their memory and spatial learning while increasing neuron counts in the hippocampus.
“This research demonstrates that mRNA therapies have the potential to expand from infectious diseases into neurological treatments,” said Maria Bergamasco, the first author of the paper published in the international academic journal Advanced Science, according to BigGo 財經.
The new drug avoids the blood-brain barrier by using the nasal mucosa as a protein synthesis factory rather than relying on intravenous injections. Large protein molecules typically cannot reach the brain because endothelial cells surrounding blood vessels block them. By dropping the mRNA liquid into the nasal cavity, the drug reaches the brain directly to support nerve cell survival and memory function.
The treatment proved effective even independently of amyloid-beta proteins, which form plaques that damage nerve cells when they detach and clump together. The BDNF produced by the mRNA did not reduce these amyloid plaques, yet it still preserved brain function during trials. Researchers said that this approach could work in tandem with existing anti-amyloid treatments to create a synergistic effect.
Mice that received the treatment twice a week from two months of age showed no cognitive decline by four months, despite normally developing dementia pathology and cognitive losses at that stage. Because human and mouse nasal cavities differ in structure, human clinical trials remain necessary before commercialization. The research team plans to begin clinical trials within two years.
The University of Sydney, founded in 1850, is Australia’s oldest university and one of the first in the world to admit students solely on academic merit and women on the same basis as men. Its researchers have included five Nobel laureates, and the institution has educated eight Australian prime ministers, including Anthony Albanese, along with 26 High Court justices and 110 Rhodes Scholars.
* What does the nasal mRNA spray actually do in the brain?
The spray delivers mRNA encapsulated in lipid nanoparticles to produce brain-derived neurotrophic factor, a protein that supports neuron survival and memory functions.
* When will human trials begin for this Alzheimer’s treatment?
The research team at the University of Sydney plans to launch human clinical trials within two years.
* Does the treatment remove amyloid-beta plaques?
The therapy preserves brain function and memory without reducing amyloid-beta plaques, operating independently of traditional plaque-clearing antibody treatments.